INTRODUCTION
Tissue factor (TF) (also known as F3, coagulation factor III or thromboplastin), a 47-KDa transmembrane glycoprotein and the primary initiator of the coagulation cascade (1), plays a critical role in homeostasis and thrombosis (2). It functions as a high-affinity receptor for the serine proteases factors VII and VIIa. The resulting TFVIIa complex activates both factors IX and X leading to thrombin generation and fibrin formation (1) . TF-induced coagulation is regulated by a specific inhibitor termed Tissue factor pathway inhibitor (TFPI). The mechanism of inhibition by TFPI involves its binding first to factor Xa and then to the VIIa/ TF complex (1).
In the last few years, it has become evident that TF is involved in various other (patho) physiological processes apart from homeostasis, such as embryonic development, transmision of signals, promotion of cell migration, adhesion, tumor initiation, growth, and inflammation (3) . Concomitantly, TFPI, the physiologic inhibitor of TF, has also been widely implicated in the regulation of those non-homeostatic functions of TF (4) . TF is essential for the normal embryonic development and its absence could lead to a defective vessel development and embryonic death in mice (5) . The expression of TF is deregulated in many cancers, and this up-regulation is often linked with aggressive malignancies (6) and increased tumor growth (7) . Moreover, expression of TF amplifies the inflammatory reaction in patients with sepsis (8, 9) . TF contributes to pathologies by activation of the coagulation cascade (proteolysis dependent signaling) as well as by coagulation-independent (proteolysis independent) signaling events via the cytoplasmic domain of TF (3, 10) . Thus, TF might not only function as the initiator of coagulation but also as a transmembrane signaling receptor which regulates angiogenesis, tumor growth, metastasis, and inflammation. Therefore, understanding the transcriptional regulation of TF expression and its inhibitor, TFPI, would appear to be a critical step in the control of many different processes.
The PAKs are serine/threonine kinases that were originally identified as binding partners and downstream effectors of Cdc42 and Rac1 in actin reorganization and cell migration (11) . PAK1, the best-characterized member of the PAK family, is activated by the p21ras-related proteins Cdc42 and Rac1 (11) , but also by a wide variety of extracellular signals (12) which promote PAK1's auto-phosphorylation and stimulation of its kinase activity (13) . PAK1 kinase activity has been implicated in a wide variety of cellular processes, including, cell motility, survival and proliferation, morphogenesis, cytoskeleton remodeling, and transcription (14) . In addition to its wellcharacterized kinase activity, the PAK1 pathway also affects nuclear events in a profound manner (15) (16) (17) and also regulates the transcription of target gene chromatin (18) (19) (20) .
During a previous gene profiling study that includes wild-type (WT) and knock-out PAK1 (PAK1-KO) mouse embryonic fibroblasts (MEFs), we identified TF and TFPI to be down-and upregulated, respectively, in the PAK1-KO MEFs in comparison to its wild type controls (RK, unpublished data), suggesting that PAK1 might regulate the expression of TF and TFPI. Given the involvement of TF, and TFPI, in several pathological and physiological events, the present study was undertaken to investigate the genomic regulation of TF and TFPI by PAK1 signaling. To date, nothing is known about the regulation of TF expression by PAK1 in cancer cells. We discovered, for the first time, that PAK1 signaling stimulates and inhibits the transcription of TF and TFPI, respectively, and modulates the coagulation process.
EXPERIMENTAL PROCEDURES
Cell culture, Antibodies and Reagents. HeLa, HEK 293T and MDA-MB-231 cells were obtained from American Type Culture collection (ATCC), and cultured in Dulbecco's modified Eagle's medium/F12 supplemented with 10% fetal bovine serum and 1X antibiotic-antimycotic solution in a humidified 5% CO2 at 37°C. PAK1 WT and KO mouse embryonic fibroblasts (MEFs) have been described earlier (21). Sources of antibodies were as follows: mouse anti-phospho-PAK1 (Thr 212) (Sigma-Aldrich, St. Louis, MO), Rabbit anti-PAK1 (Bethyl laboratories, Montgomery, TX), mouse anti-Tissue Factor (10H10) (Novus Biologicals, Littleton, CO), mouse anti-vinculin (Sigma-Aldrich, St. Louis, MO), rabbit anti-c-JUN (Santa Cruz Biotechnologies, Santa Cruz, CA), mouse anti-myc Tag (9B11) (Cell Signaling Technology, Danvers, MA), and mouse anti-Flag M2 (Sigma-Aldrich, St. Louis, MO). Normal mouse IgG, and rabbit IgG were from SigmaAldrich (St. Louis, MO). All primary antibodies were used as according to manufacturer's instructions. Horseradish peroxidase-conjugated secondary antibodies were from GE Healthcare (Piscataway, NJ), and enhanced chemiluminescence (ECL) reagents were from Amersham Biosciences (Piscataway, NJ). The blocking antibody for human Tissue factor TF8-5G9 was a generous gift of Dr. James H.
Morrissey (University of Illinois).
Expression vectors, recombinant proteins, siRNAs, and transfections. Expression vectors encoding PAK1-myc, PAK1 T423E, and PAK1 K229R were generously provided by Jonathan Chernoff (Fox Chase Cancer Center, Philadelphia, PA) and have been previously described (22), pCDNA3.1-PAK1, and GST-PAK1 have been described previously (23). pcDNA-c-JUN-Flag (c-JUN-Flag) and GST-c-JUN have been used previously (24). The dominant negative mutant of c-JUN was a generous gift from Dr. Powell H. Brown (National Cancer Institute, NIH, Rockville, Maryland, MD) and has already been described (25). All GST recombinant proteins were expressed in E. coli strain BL21 (DE3) (Stratagene, La Jolla, CA) and subsequently purified using the Glutathione Sepharose 4B batch method (GE Healthcare, Piscataway, NJ -ACC TGG AAA CCA TTC GGA  CCA TCT-3', m18S_F: 5'-CCG GAG CTA GGA  ATA ATG GA-3', m18S_R: 5'-CCC TCT TAA  TCA TGG CCT CA-3', mTF_F:5'-AGA ACA  CCC CGT CGC GCT TG-3', mTF_R: GCT CTC  CGC AAC AGT GCC GT-3', mTFPI_F: 5'-TGT  TGC TTA GCC TTG TTC CCG AGT-3', and  mTFPI_R: TGC TTT GCA TGG ACC ATC ATC  TGC-3 '. All qPCR primers were synthesized in Sigma-Aldrich (St. Louis, MO).
Western Blot and Immunoprecipitation. Protein extracts were prepared by lysing the cells in the RIPA buffer containing 50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1×protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN), and 1× phosphatase inhibitor cocktail I and II (Sigma-Aldrich, St. Louis, MO), and protein concentrations were determined using Bio-Rad DC Protein Assay reagents (Bio-Rad Laboratories, Hercules, CA). Cell extracts were then resolved by SDS-PAGE, transferred to nitrocellulose membranes, and incubated with the indicated antibodies. Detections were performed using the ECL reagents. For immunoprecipitation (IP) analysis, total 1 mg of protein materials was incubated with 1 µg of primary antibody overnight at 4 ° C on a rocket platform, followed by incubation with total 50 µl of protein A/G PLUSagarose (Santa Cruz Biotechnology, Santa Cruz, CA) or Trueblot IP beads (eBioscience, San Diego, CA) for 2 h at 4 °C. The immunoprecipitates were collected by centrifugation in a microcentrifuge at 6000 rpm for 5 min. The supernatant was discarded, whereupon the pellet was washed with Nonidet P-40 buffer (NP40 lysis buffer) (50 mM Tris-HCl, pH 8.0, 0.5 % Nonidet P-40, 10 % Glycerol, 150 mM NaCl, 2 mM MgCl 2 , and 1 mM EDTA), with protease inhibitors for three to five times and then dissolved in a sample buffer for SDS-PAGE.
GST pull-down assays. The GST pull-down assays were performed by incubating equal amounts of GST or GST fusion protein immobilized to glutathione-Sepharose beads with in-vitro translated 35 S -labeled protein, in a 400 µl reaction volume. The mixtures were incubated for 2h at 4 °C and washed three to six times with NP40 lysis buffer. Bound proteins were eluted with 2x SDS buffer, separated by SDS-PAGE and visualized by autoradiography. The transferred protein on the blot was visualized using Ponceau S stain.
Chromatin Immunoprecipitation (ChIP) and reChIP assays. The ChIP assays were performed as described previously (27). Briefly, approximately 10 6 cells were treated with 1% formaldehyde (final concentration) for 10 min at 37°C to cross-link histones to DNA and washed twice with phosphate-buffered saline containing protease inhibitors cocktail. Cells were lysed by sonication and immunoprecipitated with specific antibodies. The immunoprecipitates were washed, the DNA was eluted off the beads, and purified DNA (phenol-chloroform extraction) was subjected to PCR. PCR primers for ChIP assays for TF and TFPI promoters are provided in supplemental Tables 1 and 2 , respectively. For re-ChIP assays, the first ChIP using a PAK1 antibody (Bethyl laboratories) was followed by a second ChIP using a c-JUN antibody (Santa Cruz biotechnology). Quantification of the bands amplified by PCR was done using ImageJ software.
Electrophoretic Mobility Shift Assay. Nuclear extracts were prepared using a Nonidet P-40 lysis method (28). EMSA for the binding of different transcription factors was performed using the annealed and [γ-32 P] ATP end-labeled oligonucleotides in a 20-µl reaction mixture for 15 min at 20 °C.
Samples were run on a nondenaturing 5% polyacryalmide gel and imaged by autoradiography. Supershift EMSAs were performed by incubating the nuclear extracts with 2µg of either the PAK1 (Bethyl laboratories, Montgomery, TX) or the c-JUN (Santa Cruz Biotechnology, Santa Cruz, CA) antibody for 1 hour before the addition of the radiolabeled oligonucleotides. Oligonucleotides used are listed in supplemental Table 3 .
Tissue Factor procoagulant activity (PCA) assay. TF activity, measured as the amount of FXa generated, was determined using the AssaySense Human TF Chromogenic Activity Assay Kit (AssayPro) with minor modifications, according to Drake TA et al (29). Cells were detached by brief exposure to Trypsin-EDTA, washed three times with DMEM/F12 and resuspended in DMEM/F12 at 4 x 10 5 cells/ml. For blocking cell-surface expressed TF, anti-TF mAb TF8-5G9 (10µg/ml) was incubated with 1ml of the corresponding intact cell suspensions for 15 min at 37 °C, washed three times with DMEM/F12 and divided into two equal portions. One portion was resuspended in Hepes-saline buffer (25mM Hepes, 0.85% NaCl, pH 7.4) and kept at 4 °C before assay of intact cell surface TF activity. The other portion was lysed by freezing the cell suspension at -70 °C for 15 min and solubilization with 15mM octyl-β-Dglucopyranoside at 37 °C for 15 minutes for assay of total TF procoagulant activity. Identical aliquots of intact (cell surface TF PCA) and lysed cells (total TF PCA) were assayed, following the manufacturer's recommendations, and the amount of FXa generated was determined by reading the absorbance at 405nm every 2 minute for 20 minutes, using a kinetic 96 well microplate reader (Synergy-H1 Hybrid Reader, Biotek).
RESULTS AND DISCUSSION

PAK1 up regulates the expression of Tissue factor
Microarray gene profiling study that includes wild-type (WT) and PAK1-knockout (KO) mouse embryonic fibroblasts (MEFs) was performed to identify the new genes or pathways that are influenced by PAK1 (RK, unpublished data). When the statistically significant differentially expressing genes were studied using Ingenuity Pathway Analysis, a total of 16 genes assigned to thrombosis were differentially expressed in between wild-type and PAK1-KO MEFs (Table  1) . These findings raise a new interesting line of research and for the first time; introduce PAK1 as a possible new regulatory player in thrombosis.
In the microarray analysis, TF, the primary initiator of the coagulation cascade, was remarkably found to be differentially expressed between both cell lines. The expression of TF was 2.53-fold down-regulated in the PAK1-KO compared to wild-type MEFs (Table 1) . Consistent with the above data, RT-quantitative PCR confirmed that TF expression was down-regulated in the PAK1 KO MEFs as compared with its wildtype counterparts (Fig. 1A) , positioning TF as a potential downstream target of PAK1. Through its impact on the coagulation cascade and cellular signaling, TF acts as an important regulator of vascular development, several cancer-related processes, such as hypercoagulability, angiogenesis and metastasis, and inflammation (3). Therefore, the knowledge of its transcriptional regulation will be of great scientific interest.
A previous study already implicated PAK1 in the regulation of TF expression in PASMCs (30). These authors observed that PAK1 is involved in thrombin signaling in PASMC and regulates the expression of TF by activating p38MAPK, PDK1 and PKB, and thus, PAK1 could play a role in vascular remodeling. Given the stablished connection between malignancy and hypercoagulant states (31) and PAK1's role in malignant processes (32), as well as the linkage of TF with cancer related processes (6,33), the possible role of PAK1 as a modulator of thrombosis in cancer cells was viewed of high interest for a more in depth study. To date, nothing is known about the regulation of TF by PAK1 in cancer cells. Further studies in the human epithelial cancer cell lines, such as HeLa and MDA-MB-231, demonstrated that the serum induction of PAK1 activity induced up regulation of TF protein as well as mRNA levels ( Fig. 1B and C), suggesting a role of PAK1 in the regulation of TF expression.
PAK1 is required for TF up regulation by serum
Since the induction of TF by serum has been well described (34), to further demonstrate the implication of PAK1 in the regulation of TF expression by serum, we examined the effect of PAK1 down regulation conditions on TF expression. As shown in Fig. 2A , PAK1 down regulation by siRNA transfection in HeLa cells compromised the ability of serum to stimulate TF protein as compared to cells transfected with a control siRNA. The induction of TF mRNA expression was also analyzed in wild-type and PAK1-KO MEFs (Fig. 2B) . The results show that the serum induction of TF mRNA observed in the wild-type MEFs was almost completely abolished in PAK1-KO MEFs, highlighting the significance of PAK1 in the regulation of TF expression.
We next examined whether the kinase activity of PAK1 is essential for the regulation of TF expression. To test this, we analyzed the effect of a dominant-negative K229R and catalytically active T423E PAK1 mutants (22,35) on the expression of TF by serum (Fig. 2C ). Transient transfection of HeLa cells with the catalytically active T423E PAK1 mutant resulted in a superior stimulation of TF protein and mRNA by serum as compared to the control cells (Fig. 2C ). On the other hand, cells expressing the kinase-dead K229R PAK1, partially suppressed the ability of serum to stimulate TF protein and mRNA expression levels (Fig.  2C ). These results demonstrate the significance of PAK1 expression and activity in the induction of TF expression by serum.
PAK1 recruitment onto TF promoter
The previously observed nuclear localization of PAK1 (18), as well as its already reported modulatory effect in the transcription of some genes, such as nuclear factor of activated T-cell (NFAT1) and the phosphofructokinase-muscle isoform (PFKM) (18), prompted us to investigate the direct genomic regulation of TF transcription by PAK1 in cancer cells.
Therefore, we examined the recruitment of PAK1 in the promoter of TF using a ChIP-based promoter walk assay. To this end, cross-linked chromatin from HeLa cells was immunoprecipitated with an anti-PAK1 antibody or IgG, and then PCR-amplified using primers designed against about every 400-base pair (bp) region of the TF promoter (Fig. 3A) . Results from Fig. 3B show that PAK1 was recruited to the TF promoter at a region encompassing -666 to -1529 bp from the transcription start site (TSS). In an attempt to narrow down the region of the TF promoter in which PAK1 was recruited, regions 3 and 4, which are positive for PAK1 recruitment, were subdivided further into two smaller regions, of about 200 bp each. New primers encompassing these regions were designed, and the same purified eluted DNA was PCR-amplified using these primers (Fig. 3C ). We discovered that PAK1 was indeed recruited to the regions 3.2 to 4.2, but not to the region 3.1 (Fig. 3C) . Our results indicate, for the first time, that PAK1 is able to specifically bind to the TF promoter region, demonstrating that TF is a target of PAK1.
Involvement of c-JUN transcription factor in PAK1-mediated TF up regulation
Since PAK1 lacks transcriptional activity but is able to induce TF expression, we next hypothesized that PAK1 might be co-recruited to the TF promoter along with a transcription factor, which could be responsible for the direct stimulation of TF transcription. For this reason, we next performed a sequence analysis of the TF promoter-PAK1 interacting regions (regions 3-4, see Fig. 3B ) using the Promo 3.0 software (36) to identify the putative binding sites for transcription factors that might be responsible for the PAK1-mediated stimulation of TF transcription. The complete list of the resulting transcription factor binding sites is presented in Table 2 . We found that TF promoter harbors binding sites for some transcription factors already involved in cell growth, proliferation and cancer related signaling events. These included TCF-4E, GATA-1, TFII-I, PXR-1: RXR-alpha, c-ETS-1, or AP-1/c-JUN (37-42). Similarly, the involvement of both PAK1 and TF in such processes has been well stablished (13, 33) . Therefore the above mentioned transcription factors appear to be good candidates for PAK1-mediated TF transcriptional up regulation.
To assess the above possibility, we examined the direct recruitment of these transcription factors to the TF promoter by electrophoretic mobility shift assay (EMSA) (Fig. 4A) . To this end, we designed double-stranded oligonucleotides, containing the binding site(s) for each transcription factor(s), that were radiolabeled, and the binding of each transcription factor was analyzed using nuclear extracts from control and serum-stimulated HeLa cells. After electrophoresis and autoradiography, we detected the formation of DNA-protein complexes with the oligonucleotides containing binding sites for AP-1/c-JUN as well as TFII-I binding site b among the tested transcription factors (Fig. 4A ). In addition, the observed complex was induced in serumstimulated HeLa cells compared to non-stimulated cells, only when using the specific oligonucleotides for AP-1/c-JUN binding site ( In addition, the observed complex could be highly inhibited, especially under serum-induced conditions, in the presence of an anti-c-JUN antibody, as well as in the presence of an anti-PAK1 antibody, but not with a control immunoglobulin IgG antibody, suggesting the coexistence of PAK1-and c-JUN/DNA complex(s). However, the presence of an anti-c-JUN antibody failed to exhibit the appearance of a super-shifted band, probably due to inefficient blocking of the recognition site for c-JUN in the DNA sequence and/or antibody-specific reasons.
To gain a deeper insight into the molecular mechanism involved in c-JUN regulation of TF expression, we next analyzed the in vivo recruitment of c-JUN to the TF promoter by chromatin immunoprecipitation (ChIP), using cross-linked chromatin from HeLa cells. We found the recruitment of c-JUN onto the region 3 of the TF promoter (Fig 4C) . This is in agreement with the Promo 3.0 sequence analysis of the TF promoter-PAK1 interacting DNA region, which indicates this region comprises the binding site for c-JUN.
The regulation of TF gene expression by c-JUN has been demonstrated in human monocytic and endothelial cells (43,44), as well as in cultured fibroblasts (45). However, the binding region of c-JUN reported in these studies (located at a region around -200 to -220 bp, relative positions to the transcription start site (43-45)) is different from the one detected in the present study (-1450 bp, relative to the transcription start site). On the other hand, a previous report located elements required for serum and phorbol miristate acetate (PMA) induction of TF promoter in HeLa cells in a region between -96 and +121 bp, from a total region analyzed of 300 bp relative to the transcription start site (46). This region lacks any AP1/c-JUN binding site, but it is possible, however, that c-JUN could account for the induction of TF gene transcription by serum in HeLa cells in a different region than the analyzed in the previous study (46) as compared to results obtained in the present study. The apparent controversy between different results could be explained by the fact that the TF gene is expressed in a cell type-specific manner (29). Moreover, our results suggest that not only the expression of TF appears to be mediated by distinct regions of the TF promoter in different cell types, but also, the induction in response of different stimuli can be mediated by distinct regions of the promoter in the same cell type.
Results from Fig. 4B , as well as the fact that c-JUN is recruited to the TF promoter region 3 (R3) (Fig. 4C) , suggest that both PAK1 and c-JUN could be co recruited at the same region onto the TF promoter. To determine whether the PAK1/c-JUN complex associates to the same region onto the TF promoter, a sequential double-ChIP analysis using the indicated antibodies was performed. We found that indeed, PAK1 and c-JUN are co-recruited onto the c-JUN-TF promoter interacting region R3 (Fig. 4D) , demonstrating the co recruitment of both proteins onto the TF promoter.
To further demonstrate the importance of c-JUN in PAK1-mediated TF up regulation, HeLa cells were co-transfected with the catalytically active mutant of PAK1 (T423E), and with a dominant negative mutant of c-JUN (TAM 67) that can repress its transcriptional activity (25). The cells were induced with serum for the indicated times, prior to the analysis of TF expression by qPCR. The presence of a dominant negative mutant of c-JUN partially suppressed the ability of the catalytically active mutant of PAK1 to stimulate TF mRNA expression after serum induction (Fig. 4E) , confirming the involvement of c-JUN in the regulation of TF expression by PAK1.
PAK1 physically interacts with c-JUN.
It has been previously reported that PAK1 activates JNK, resulting in the phosphorylation and activation of c-JUN (47) . However, our findings that PAK1 and c-JUN are co recruited onto the TF promoter raises the possibility of physical interaction between them. To test this notion, HEK293T cells were co-transfected with expression vectors encoding Flag-tagged c-JUN and Myc-tagged PAK1, and protein extracts were subjected to the sequential immunoprecipitation/Western blot (WB) analysis.
Results from Fig. 5A show that, indeed, exogenously expressed Flag-c-JUN but not control IgG could be coimmunoprecipitated with Myc-PAK1, suggesting that the two proteins interact in vivo. In addition, similar interaction was observed between PAK1 and c-JUN at the endogenous protein level in HeLa cells (Fig.  5B) . To determine whether PAK1 directly binds to c-JUN, we next performed in vitro GST pull-down assays using 35 S-labeled, in vitro-translated c-JUN protein and full-length GST-PAK1 fusion protein, as well as 35 S-labeled, in vitro-translated PAK1 protein and full-length GST-c-JUN fusion protein, and found that 35 S-labeled c-JUN and 35 S-labeled PAK1 strongly bound to GST-PAK1 and GST-c-JUN proteins respectively (Fig. 5C and D ). These findings demonstrate that PAK1 physically associates with c-JUN both in vivo and in vitro. It is noteworthy that PAK2 is also shown to bind and phosphorylate c-JUN modulating its activity (48) .
Given the similarity in the phosphorylation recognition motifs of PAK1 and PAK2, these results suggest that PAK1 interaction with c-JUN promotes its transcriptional activation and leads to induction of TF expression.
PAK1 stimulation regulates the procoagulant activity of Tissue factor.
To investigate the possibility of PAK1 involvement in the coagulation cascade triggered by TF, we analyzed the TF activity, as means of its ability to activate Factor X (FX) to FXa. The amount of FXa generated was quantitated using a highly specific FXa substrate releasing a yellow para-nitroaniline (pNA) chromophore. The change in absorbance of the pNA at 405 nm is directly proportional to the TF enzymatic activity. HeLa cells transiently over-expressing the dominantnegative K229R or catalytically active T423E PAK1 mutants, or control cells (empty vector) stimulated or not with serum for 3 hours were used for these experiments (Fig. 6) .
The corresponding intact cell suspensions were incubated with either control or anti-TF antibody for 15 min at 37°C and then washed to remove unbound antibody before cells were either lysed (for assay of total TF activity) or collected (for assay of cell surface TF activity), and the TF activity measured. As previously reported (49), intact HeLa cells expressed very little cell surface TF activity compared to the total TF activity in disrupted cells (data not shown). In addition, the presence of the TF blocking antibody was able to reduce <5% of the total activity (data not shown), thus indicating that the majority of TF in HeLa cells was expressed intracellularly, which is in agreement with previous reports (49) . The presence of an intracellular pool may be particularly important because it is likely to be protected from extracellular inhibitors of TF. Furthermore, previous studies have found that a substantial portion of TF is not active on the surface of unperturbed cells, and have suggested that much of the TF is encrypted on the cell surface (50) . Therefore, to further verify the implication of TF in the generation of FXa, the experiment was performed in the absence of FVII. This approach completely blocked all the activity (data not shown), thus demonstrating that the results obtained were entirely due to TF activity.
In order to gain insight into the ability of PAK1 to induce TF procoagulant activity, we monitored the ability of the endogenously expressed TF to enhance the specific proteolytic activation of FX to FXa during the whole assay (Fig. 6A and B) . This is achieved through the constant annotation of the change in absorbance of the released chromophore pNA at 405 nm. A clear increase in the TF procoagulant activity during the whole analysis was observed after serum treatment of the control and T423E PAK1 expressing cells, and this induction was more notable in cells expressing the catalytically active form of PAK1, T423E (Fig.  6A ) . On the contrary, serum was unable to further induce any TF activity in cells expressing the dominant negative PAK1 mutant (K229R) (Fig.  6B ).
Active TF was determined from the standard curves generated, at two different time points (10 and 20 minutes), using known concentrations of a recombinant human TF preparation, and expressed as pM of TF per number of cells (Fig. 6C) . We found that control cells as well as catalytically active mutant PAK1 (T423E) cells showed a higher level of active TF after serum stimulation. Moreover, cells expressing the catalytically active PAK1 (T423E), showed even a higher level of active TF in serum stimulation conditions, as compared to control cells. However, the levels of active TF remained without any change in cells transiently transfected with the kinase dead mutant of PAK1 (K229R) (Fig. 6C) , thus highlighting the implication of PAK1 activation in the control of TF coagulation activity. Together, these results implicate PAK1 signaling acts as a modulator of the coagulation protease cascade, by playing a role in the modulation of TF ability to activate FX.
PAK1 recruitment onto TFPI promoter and modulation of its expression
The above results demonstrate the significance of PAK1 signaling in the coagulation cascade triggered by TF. Interestingly, the natural inhibitor of the TF-mediated coagulation, Tissue Factor Pathway inhibitor (TFPI), was also found to be differentially expressed between wild-type and PAK1-KO MEFs (Table 1) . PAK1-KO MEFs showed a 3.46 fold up regulation of TFPI compared to wild-type MEFs, suggesting a possible negative regulation of TFPI expression by PAK1.
RT-quantitative PCR analysis confirmed the up regulation of TFPI in the PAK1-KO cells as compared with its wild-type counterparts (Fig.  7A) . Furthermore, serum induction of PAK1 in HeLa and MDA-MB-231 human cell lines led to down regulation of TFPI mRNA expression (Fig.  7B and C, respectively) , suggesting that PAK1 can negatively modulate the expression of TFPI. Similar to TF, the expression of TFPI has also been reported to be modulated by serum (51) . Hence, further studies were designed to demonstrate the significance of PAK1 signaling in the down regulation of TFPI expression. To this end, we analyzed the expression of TFPI mRNA in PAK1-KO MEFs or wild-type MEFs under serum stimulation conditions. We found a down regulation of TFPI mRNA levels by serum stimulation in the wild-type MEFs, and this down regulation was not only compromised in the serum stimulated PAK1-KO MEFs, but we observed instead a transient up regulation of TFPI mRNA expression levels in these cells, suggesting that PAK1 may be essentially involved in the repression of TFPI expression.
We next investigated the importance of PAK1 kinase activity in the regulation of TFPI expression. We analyzed the effect of the dominant-negative K229R and catalytically active T423E PAK1 mutants (22,35) on TFPI mRNA expression after serum induction (Fig. 7E) . As expected, serum induction of cells overexpressing a kinase-dead PAK1 mutant (K229R) resulted in a progressive up regulation of TFPI mRNA expression, but no stimulation of TFPI mRNA levels was observed in those cells expressing the catalytically active PAK1 mutant (T423E). Results from Fig. 7 D and E suggest that PAK1 expression and activation negatively regulates TFPI expression at the transcriptional level. To further strengthen this hypothesis, we next explored the recruitment of PAK1 to the promoter of TFPI using a ChIP-based promoter walk assay in cross-linked chromatin from HeLa cells immunoprecipitated with an anti-PAK1 antibody or IgG control antibody. A region of the human TFPI promoter of approximately 1700 base pairs (+25 to -1653 bp relative positions from the TSS) was analyzed by PCR using primers designed about each 400 bp (Fig. 7F) . As shown in Fig. 7G , ChIP results showed the recruitment of PAK1 onto the TFPI promoter to a region encompassing -798 to -1198 bp from the TSS, named Region 3 (R3). In summary, results from Fig. 7 demonstrates, for the first time, that PAK1 is recruited to the TFPI promoter and that PAK1 acts as a negative modulator of TFPI expression.
Balanced levels of TF and TFPI are essential to maintain normal homeostasis. In this regard, the ability of PAK1 to up regulate TF expression, and down regulate TFPI expression places PAK1 as a new key molecule involved in the deregulation of normal homeostasis. In agreement with the results presented here, previous work from Diebold et al demonstrates the expression of PAK1 in the media of remodeled pulmonary vessels from patients with pulmonary vasculopathy and its implication in vascular remodeling by thrombin signaling in pulmonary artery smooth muscle cells (PASMCs) (52) . Future studies, with the use of smooth muscle cells are guaranteed in order to better elucidate the role of PAK1 in thrombosis. From another point of view, given the role of PAK1 as a central signaling transducer and the emerging functions of TF, as well as of TFPI in different signaling events apart from homeostasis (53, 54) , our findings open a new transcriptional regulatory axis that could be highly relevant not only in coagulation, physiological signaling pathways, but also in several malignant processes.
In summary, we provide here a novel regulatory mechanism of TF expression and procoagulant activity in epithelial cancer cells by PAK1-c-JUN complex. Furthermore, PAK1 is able to bind to the TFPI promoter, and negatively regulates its expression, presumably releasing the inhibition of the TF-FVIIa complex from TFPI, and in-turn, contributing to a hypercoagulant state (Fig. 7H ). Our working model provides a novel function for PAK1 in the control of coagulation processes, suggesting that the control of PAK1 activity may act as a new and exciting potential therapeutic strategy. Tanikawa, M., Wada-Hiraike, O., Nakagawa, S., Shirane, A., Hiraike, H., Koyama, S., Miyamoto, Y., Sone, K., Tsuruga, T., Nagasaka, K., Matsumoto, Y., Ikeda, Y., Shoji, K., Oda, K., Fukuhara, H., Nakagawa, K., Kato, S., Yano, T., and Taketani 
